Lanadelumab (SHP643) is a humanized IgG1 monoclonal antibody targeting plasma kallikrein (pKal) with a Ki value of 0.12 nM. Lanadelumab effectively inhibits both free pKal and its interaction with high molecular weight kininogen (HMWK)-bound pKal. Lanadelumab has demonstrated potential in hereditary angioedema research and represents a promising therapeutic antibody for studying kallikrein-kinin system regulation.
Reinheit:
95.00%
CAS Nummer:
[1426055-14-2]
Target-Kategorie:
Serine Protease
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten